"目录号: HY-15255
Membrane Transporter/Ion Channel-
Zosuquidar (LY335979)是P-糖蛋白（P-gp）介导的多药抗性调节剂，Ki为60 nM。
相关产品
Elacridar-Zosuquidar trihydrochloride-Tariquidar methanesulfonate, hydrate-Valspodar-(20S)-Protopanaxadiol-Dofequidar fumarate-Piperine-HM30181-Alisol F-Polyoxyethylene stearate-Biricodar-MCI826-
生物活性
Description
Zosuquidar (LY335979) is a potent modulator of P-glycoprotein-mediated multi-drug resistance with Ki of 60 nM.IC50 value: 60 nM (Ki)Target: P-glycoproteinZosuquidar (LY335979) is a potent modulator of P-glycoprotein-mediated multidrug resistance with Ki of 60 nM. Zosuquidar binds with high affinity to P-glycoprotein and inhibits P-glycoprotein-mediated multidrug resistance (MDR). P-glycoprotein, encoded by the MDR-1 gene, is a member of the ATP-binding cassette superfamily of transmembrane transporters and prevents the intracellular accumulation of many natural product-derived cytotoxic agents. Zosuquidar is a compound of antineoplastic drug candidates currently under development.
Clinical Trial
Kanisa Pharmaceuticals
Leukemia, Myeloid
October 2005
Phase 1-Phase 2
Eastern Cooperative Oncology Group-National Cancer Institute (NCI)-Eli Lilly and Company-Kanisa Pharmaceuticals
Leukemia-Myelodysplastic Syndromes
July 2002
Phase 3
Kanisa Pharmaceuticals
Leukemia, Myeloid
August 2005
Phase 1-Phase 2
View MoreCollapse
References
